Drug Information Association Logo
Corporate Tagline

Evaluation and Management of Cardiac Conditions in Oncology Patients

Dec 3 2013 11:00AM - Dec 10 2013 12:30PM | Online

« Back to Listing


This webinar will be broadcast in Eastern Time (ET)

Cardio-oncology focuses on cardiovascular safety monitoring and management of cardiovascular toxicities of oncology drugs during development and post-approval. The discipline evolved as there is a prevalence of cardiotoxicities associated with cancer therapeutics and a need for clearly defined cardiovascular risk management for their development. This two-part webinar series will review different critical topics in the evaluation and management of cardiac conditions in oncology patients

Part I: Updates in Cardio-oncology
This webinar will present topics critical to the evaluation of cardiac safety as it pertains to oncology drug development, and will provide an understanding of the investigations in the unique setting of drug therapy for treatment of cancer patients. Issues such as QT evaluation, troponin monitoring, and cardiac imaging will also be reviewed.

Part II: Treatments
This webinar will expand on the learnings from part I and discuss the cardiac evaluation of patients in the clinic – both in drug development as well as in oncology clinical practice.  The presentations will be followed by a question and answer period which will allow participants to get further explanations on managing these challenging cardiovascular issues from people actively engaged in this area.

This webinar was developed in collaboration with the Cardiac Safety Research Consortium

Featured Topics 

Part I:  Updates in Cardio-oncology

Daniel Lenihan MD, FACC
Professor, Division of Cardiovascular Medicine
Director, Cardiovascular Clinical Research
Vanderbilt University

John Finkle MD, FACC, FACP
Vice President, Clinical Safety and Pharmacovigilance

QT Interval Evaluation During Oncology Drug Development
John Finkle MD, FACC, FACP

Use of Troponin and Other Biomarkers in Oncology Patients
Daniel Lenihan, MD
Vanderbilt University

Cardiac Imaging (Echo, MRI)
Juan Carlos Plana, MD
Cleveland Clinic

Part II: Treatments

John Finkle, MD FACC FACP
Vice President, Clinical Safety and Pharmacovigilance

Daniel Lenihan MD, FACC
Professor, Division of Cardiovascular Medicine
Director, Cardiovascular Clinical Research
Vanderbilt University

Follow Up of CV events
Mary Beth Sabol, MD
Safety Development Leader
Global Clinical Safety and Pharmacovigilance

Blood Pressure Management During Anti-angiogenic Therapy for Cancer
Philip Sager, MD, FACC, FAHA, FHRS
Consulting Professor of Medicine, Stanford University
President, Sager Consulting Experts, Inc.
Chair, Scientific Program’s Committee, Cardiac Safety Research Consortium

Optional Management of Cardio-toxicity During Drug Development
Joseph Carver, MD
Senior Administrative Officer, Cardiology
Abramson Cancer Center

Who Should Attend 

Professionals with intermediate to advanced knowledge of, and experience in:

  • Safety / Pharmacovigilance
  • Drug Development
  • Risk Management

Learning Objectives 

Part I: Updates in Cardio-oncology
At the conclusion of this webinar, participants should be able to:

  • Evaluate the electrocardiographic QT interval during oncology drug development
  • Describe the practical aspects of using cardiac troponin levels and other biomarkers to detect and monitor for cardiotoxicity in oncology drug development
  • Discuss the practical aspects of cardiac imaging modalities to monitor cardiotoxicity in oncology drug development

Part II: Treatments
At the conclusion of this webinar, participants should be able to:

  • Explain the benefits of cardioprotective therapy for the prevention of cardiotoxicity during cancer chemotherapy
  • Recognize the practical aspects of improved follow-up of cardiovascular events in oncology drug development
  • Discuss the optimal evaluation and management of blood pressure during therapy with anti-angiogenic agents

Contact Information 

Registration Questions and Technical Support Day of Event
Customer Service Department
Phone: +1.888.257.6457 | +1.215.442.6100
Fax: +1.215.442.6199

Agenda Details and Event Logistics
Ellen Diegel, Event Planner
Phone +
Fax +1.215.442.6199

Technical Requirements 

Click here for minimum system requirements.

Technical Support Day of Event
Customer Service Department
Phone: +1.888.257.6457 | +1.215.442.6100


Previous Next

Continuing Education 

The Drug Information Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is designated for 3 contact hours or .3 continuing education units (CEU’s). Type of Activity: Knowledge

ACPE Credit Request Update DIA is required by the Accreditation Council for Pharmacy Education (ACPE) to report pharmacy-requested CEUs through the CPE Monitor system. All ACPE-certified activity credit requests need to be submitted through DIA’s My Transcript within 45-days post activity. Pharmacists will need to provide their National Association of Boards of Pharmacy (NABP) e-Profile ID and date of birth (MMDD) to ensure the data is submitted to the ACPE and NABP properly. If you need to obtain your NABP e-Profile, please visit www.cpemonitor.net.

Drug Information Association has been accredited as an Authorized Provider by the International Association for Continuing Education and Training (IACET), 1760 Old Meadow Road, Suite 500, McLean, VA 22102; +1.703.506.3275.

As an IACET Authorized Provider, Drug Information Association offers CEUs for its programs that qualify under the ANSI/IACET Standard. Drug Information Association is authorized by IACET to offer .3 CEUs for this program. Participants must attend the entire program in order to be able to receive an IACET statement of credit. No partial credit will be awarded.

This program is part of DIA’s Certificate Program and is awarded the following:
• Clinical Safety and Pharmacovigilance Certificate Program: 2 Elective Units

For more information go to www.diahome.org/certificateprograms

Name Credit Type Max Credits CEU
Evaluation and Management of Cardiac Conditions in ACPE 3.00 0.300
Evaluation and Management of Cardiac Conditions in IACET 3.00 0.300

Disclosure Policy:

It is DIA policy that anyone in a position to control the content of a continuing education activity must disclose to the program audience (1) any real or apparent conflict(s) of interest related to the content of their presentation and/or the educational activity, and (2) discussions of unlabeled or unapproved uses of drugs or medical devices. Disclosure statements will be included in the course materials.

Statement of Credit:

If you would like to receive a statement of credit, you must participate in the live webinar, and complete the online credit request process through My Transcript. Participants will be able to download a statement of credit upon successful submission of the credit request. My Transcript will be available for credit requests on Monday, December 23, 2013.

Continuing education credits are available to learners who participate in the live webinar. Continuing education credits are not available for the archived webinar.

Pharmacy Credit Allocation
• Part 1 –Updates in Cardio-Oncology: 1.5 contact hours/.15 CEUs 0286-0000-13-098-L01-P
• Part 2 – Treatments: 1.5 contact hours/.15 CEUs 0286-0000-13-099-L01-P

To view DIA’s Grievance Policy, please visit the CE page on DIA’s website at www.diahome.org/CE


Day 1 Tuesday, December 03, 2013

  • 11:00AM - 12:30PM

    Part I: Updates in Cardio-oncology

Day 2 Tuesday, December 10, 2013

  • 11:00AM - 12:30PM

    Part II: Treatments

Registration Fees 

Other Fees

Group Site
Group Plus


Member Government Individual
Member Academia Individual
Member Individual


NonMember Government Individual
NonMember Academia Individual
NonMember Individual
Group Discounts

  • Group site registration is a license for ONE internet login allowing multiple viewers from one location.
  • Group Plus is a license for up to FIVE internet logins allowing one or more viewers at each login location.

No refunds will be provided in the event of a participant’s cancellation since all costs for this webinar have been prepaid by DIA. DIA reserves the right to modify or cancel programs and/or substitute presenters or panelists. DIA is not responsible for failure to deliver programs due to circumstances beyond its control.

Participants with Disabilities: Reasonable accommodations will be made available to persons with disabilities who attend an educational activity. Contact the DIA office in writing at least 15 days prior to event to indicate your needs.

Register Online

Unless otherwise disclosed, the statements made by speakers represent their own opinions and not necessarily those of the organization they represent, or that of the Drug Information Association. Speakers, agenda and CE information are subject to change without notice. Recording of any DIA educational material in any type of media is prohibited without prior written consent from DIA.

« Back to Listing Back To Top